Clinics in Oncology

9

Network Pharmacology and Molecular Docking Strategy Reveal the Mechanism of *Tripterygium wilfordii* in Treating Castration-Resistant Prostate Cancer

Yang X^{1#}, Yimamu Y^{2#}, Xiao W³, Jiang S^{1*} and Pan J^{1*}

¹Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, China ²Department of Urology, The Sixth Affiliated Hospital, South China University of Technology, China ³Department of Urology, The First Affiliated Hospital of Jishou University, China #These authors contributed equally to this work

Abstract

Background: Castration-Resistant Prostate Cancer (CRPC) is an inevitable type of progression in Prostate Cancer (PCa) after Androgen Deprivation Therapy (ADT). *Tripterygium wilfordii* (TW), a traditional Chinese herbal medicine, is frequently used to treat cancer and other diseases. In order to identify the potential mechanism of TW in the treatment of CRPC, we jointly utilized network pharmacology and molecular docking to perform preliminary investigation and validation.

OPEN ACCESS

*Correspondence:

Jincheng Pan, Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, No. 58 Zhongshan 2nd Road, Guangzhou, Guangdong Province, 510080, China Shuangjian Jiang, Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, No. 58 Zhongshan 2nd Road, Guangzhou, Guangdong Province, 510080, China **Received Date**: 28 Jul 2023 **Accepted Date**: 16 Aug 2023 **Published Date**: 25 Aug 2023

Citation:

Yang X, Yimamu Y, Xiao W, Jiang S, Pan J. Network Pharmacology and Molecular Docking Strategy Reveal the Mechanism of Tripterygium wilfordii in Treating Castration-Resistant Prostate Cancer. Clin Oncol. 2023; 8: 2011. ISSN: 2474-1663

Copyright © 2023 Jiang S and Pan J. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. **Methods:** The active components and corresponding protein targets of TW were screened on TCMSP database, the targets of CRPC were obtained on GeneCards database and DisGeNET database. The intersectional targets of TW and CRPC were obtained on Venn software. Then, we used STRING database to construct a PPI network based on the intersectional targets, further performed GO and KEGG enrichment analyses on the intersectional targets. Finally, molecular docking was approved for the main active components and core targets. In addition, we also carried out immunohistochemical analysis and expression analysis of core targets, which were conducted to determine how TW affects CRPC and what are the most important components, potential targets, and signaling pathways.

Results: Our study reveals that kaempferol is the key component of TW treatment for CRPC. The findings of the network pharmacology indicated that TP53, AKT1 and TNF are the potential target genes for TW connected to anti-CRPC actions. Additionally, KEGG analysis revealed that p53 signaling pathway and PI3K-Akt signaling pathway may be the driver of the anti-CRPC impact of TW. The results of molecular docking showed a high affinity between major active components in TW and the key targets in CRPC.

Conclusion: This study reveals the potential mechanisms of TW in the treatment of CPRC through multiple targets and signaling pathways and is validated through molecular docking. TW exerts pharmacological effects in CRRC, p53 signaling pathway is of great value. Furthermore, the present study provided a reference for the wide application of TW in clinically managing CRPC.

Keywords: *Tripterygium wilfordii*; Castration-Resistant Prostate Cancer; Network pharmacology; Molecular docking

Abbreviations

TW: *Tripterygium wilfordii*; CRPC: Castration-Resistant Prostate Cancer; PCa: Prostate Cancer; ADT: Androgen Deprivation Therapy; nmCRPC: non-metastatic Castration-Resistant Prostate Cancer; mCRPC: metastatic Castration-Resistant Prostate Cancer; OB: Oral Bioavailability; DL: Drug-Likeness

Introduction

Prostate Cancer (PCa) is the second most prevalent malignancy and the fifth leading cause of cancer death in males worldwide. In 2020, the global median rates of prostate cancer-related morbidity and mortality for men are 30.7/100,000 and 7.7/100,000 respectively [1,2]. The morbidity and mortality of PCa in China have been rising yearly, particularly for people over 60 years old,

albeit not being as high as in Europe and the United States [3,4]. There is a gap in the 5-year relative survival rate in PCa between China (66.4%) and developed countries (90.9%-99.5%). In addition to the different cancer spectrums between China and developed countries, late clinical diagnosis and irregular clinical diagnosis in advanced cases are the primary causes of this disparity [5]. Although Androgen Deprivation Therapy (ADT) has good efficacy for PCa patients, the majority of patients continue to convert from Hormone-Sensitive Prostate Cancer (HSPC) to Castration-Resistant Prostate Cancer (CRPC), which is divided into non-metastatic Castration-Resistant Prostate Cancer (nmCRPC) and advanced-stage metastatic Castration-Resistant Prostate Cancer (mCRPC) [6]. Currently, several new anti-androgen therapeutic agents which can prolong the MFS of nmCRPC have been recommended for the treatment of nmCRPC, such as darolutamide and enzalutamide. Though conditions of patients with initially diagnosed metastatic PCa can be improved to some extent, the majority of patients still develop mCRPC within two years [7,8]. Now, new endocrine therapies such as abiraterone and enzalutamide are recommended as first-line drugs for mCRPC, and previous studies have confirmed that these drugs benefit patients with mCRPC to a certain degree, especially patients who featured age \geq 75 years, visceral metastases, pathological glandular cavity pattern or AR-expressing activity [9]. Chemotherapeutic agents such as docetaxel and platinum, targeted therapies such as the PARP inhibitor Olaparib, and immunotherapies like PD-1 and PD-L1 inhibitors are also available for the treatment of mCRPC, but the efficacy and safety of drugs remain controversial. The multidrug resistance exhibited by PCa is a major cause of cancer recurrence, metastasis, and treatment failure [10]. In the absence of effective treatment, the median survival of mCRPC is only 12 months. Therefore, exploring new drugs to optimize the treatment of patients with CRPC is urgent to prolong patient survival, delay disease progression and improve quality of life.

As a traditional Chinese medicine and one of the most researched herbal medicines among many herbal monomers, Tripterygium wilfordii (TW) has the efficacy of activating blood circulation, clearing heat and detoxifying, anti-rheumatoid and anti-cancer, especially in the treatment of various tumors such as breast cancer [11], lung cancer [12], cervical cancer [13] and leukemia [14], etc. Its main components, such as triptolide, can act on multiple aspects of tumors, including induction of apoptosis, blocking the cancer cell cycle, inhibiting cancer cell invasion and metastasis, inducing cancer cell autophagy. However, the molecular mechanism of the TW regimen for CRPC treatment has not been fully clarified. Network pharmacology is a comprehensive research method based on theories of systems biology and genomics. It can reflect the "componenttarget-disease" relationship, which provides guidance and treatment methods for drug discovery and selection in various diseases [15]. In this study, we used network pharmacology and molecular docking to investigate the mechanism of TW for the CRPC treatment and provide a basis for subsequent clinical treatment and experimental research. The flowchart of this study is shown in Figure 1.

Materials and Methods

Identification of bioactive components and corresponding targets of TW

The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP; http://old.tcmsp-e.com/tcmsp.php) was used to obtain the components of TW, and the Oral Bioavailability (OB) \geq 30% and Drug-Likeness (DL) \geq 0.18 were used as the preset criteria to obtain the main bioactive ingredients of TW. The corresponding targets of each bioactive component in TW were gained using TCMSP database, then we established the protein-target database of TW. Finally, the target proteins were standardized in the Universal Protein Resource (Uniprot; https://www.uniprot.org/), and the target information of "Homo sapiens" was reserved for further analysis.

Collection of relevant targets of TW in the treatment of $\ensuremath{\mathsf{CRPC}}$

By using the DisGeNET database (https://www.disgenet.org/) and GeneCards database (https://www.genecards.org/), the keyword "castration resistant prostate cancer" was used to retrieve the diseaserelated targets. Intersections of TW targets and CRPC targets were regarded as the targets of TW action in the treatment of CRPC. The common targets between the components and CRPC were obtained by using the Venny 2.1.0 tool (https://bioinfogp.cnb.csic.es/tools/ venny/).

Construction of the Protein-Protein Interaction (PPI) network

We used the Search Tool for the Retrieval of Interacting Genes/ Proteins database (STRING database; https://string-db.org/) to analyze the interaction between common targets. In our study, the species was limited to "*Homo sapiens*", and the minimum required interaction score was set to be medium confidence (0.400). Then we obtained the PPI networks from the STRING database, we used Cytoscape 3.7.2 software to perform network topology analysis for obtaining the degree of connectivity between intersectional targets and mapping the network of potential target interactions based on the Degree value. Finally, we used MCC methods in the "cytoHubba" plugin of Cytoscape 3.7.2 software to identify the top 10 target genes as the hub targets.

Immunohistochemical analysis and survival analysis of core targets

We used The Human Protein Atlas database (https://www. proteinatlas.org/) to obtain the images of hub targets, then we used the GEPIA database (https://gepia.cancer-pku.cn/) to compare the expression of hub target genes in the prostate tissues of PCa patients and normal people, and also to explore the impact of core genes on survival prognosis of PCa patients.

GO and KEGG pathways enrichment analysis

We used R Studio software to perform functional enrichment analysis of the intersectional targets, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Then we used the "clusterProfiler" and "ggplot2" packages in R studio software to visualize the enriched pathways. The statistical significance threshold of enrichment analysis was P<0.05. The top 20 enriched terms were shown on a chord plot.

Construction of the component-target-signaling pathway network

We used Cytoscape 3.7.2 software to construct the "componenttarget-signaling pathway" network to clarify the relationship between bioactive compounds in TW, potential targets and main signaling pathways. Then, we analyzed the network with "Analyze network" plugin in Cytoscape 3.7.2 software to explore the main components and targets as well as demonstrate the relationship between the active components, targets, and major signaling pathways. Finally, the



network was visualized using Cytoscape 3.7.2 software.

Molecular docking simulation

We selected the main active components and hub targets in the "component-target-signaling pathway" network for molecular docking. We used PubChem (https://pubchem.ncbi.nlm.nih.gov/) to download the 3D structures of the main active components. The structures of the hub target protein were obtained from the PDB database (http://www.rcsb.org/). The target proteins were de-watered, hydrogenated, and charge calculated by using AutoDockTools 1.5.6 software, then run AutoDock Vina using "autogrid" and "autodock" plugins for molecular docking, and the Lamarckian Genetic Algorithm (LGA) was used in the docking process. Binding Energy (BE) (Kj/mol) was used to assess the binding activity between small molecules and proteins. Generally, BE \leq -5.0 Kcal/mol is considered to have good binding properties. Finally, PyMOL 2.4.0 software was used to visualize the results.

Results

Identification of bioactive components and corresponding targets of TW

We obtained 144 components of TW through the TCMSP database. After filtering by preset criteria (OB \ge 30% and DL \ge 0.18), a total of 51 active components were retrieved, the detailed information regarding these compounds is shown in Table S1. Then, we also predicted 141 potential targets which were identified for 51 bioactive components in TW through the TCMSP database. Afterward, potential targets were extracted and converted to gene names using Universal Protein Resource.

Acquisition of intersectional targets of TW and CRPC

We obtained 683 relevant targets of CRPC from the DisGeNET database and 827 from the GeneCards database. Then we used Venny 2.1.0 to obtain the intersection between the corresponding target of the bioactive components in TW and the targets of CRPC. Finally, we obtained 38 targets for the treatment of CRPC with TW (Figure 2).

PPIs network analysis of overlapping targets

To further investigate the relationship between the 38 overlapping genes, we constructed the PPIs network by using the STRING database. Then the network was analyzed and visualized by Cytoscape 3.7.2, showing a total of 38 nodes and 322 edges. The result was shown in Figure 3. After that, we used "cytoHubba" plugin to screen the top 10 hub targets, which were TP53, AKT1, TNF, VEGFA, STAT3, PTGS2, CXCL8, CASP3, MMP9 and ESR1, indicating the importance of these genes to the mechanism of TW action to CRPC.

Immunohistochemical analysis and expression analysis of core targets

The Human Protein Atlas database showed the expressions of the hub targets in prostate tissues of PCa patients and normal people were different (Figure 4). Through the analysis using the GEPIA database, by setting the standard of |Log2FC|=1 and p-value <0.01, the results showed that MMP9 expressed higher than normal prostate tissues (P<0.01), PTGS2 and VEGFA expressed lower than normal prostate tissues (P<0.01) (Figure 5). By setting the standard that: 1) group cutoff =50%, 2) p-value <0.05, the results of the Kaplan–Meier survival curves showed that the high-risk group had a lower overall survival rate than the low-risk group in the TP53 and VEGFA gene groups (Figure 6).



Figure 2: Venn diagram. 38 overlapping targets were obtained from three databases (TCMSP, GeneCards, and DisGeNET). These targets were identified as the targets of TW in the treatment of CRPC.

Docking molecular combination	Binding Energy (Kcal/mol)
triptolide-VEGFA	-8.4
triptolide-TP53	-7.4
triptolide-STAT3	-7.9
triptolide-TNF	-8.5
kaempferol-AKT1	-6
kaempferol-PTGS2	-9





GO and KEGG pathways enrichment analysis

We performed the GO enrichment analysis of 38 overlapping targets using the package "clusterProfiler" in the R. The GO enrichment analysis showed that the biological processes were mainly enriched in the pathways of cell migration, apoptosis, oxidative stress response, proliferation of immune cells, regulation of cell cycle, and autophagy regulation. The results of the KEGG pathway enrichment analysis showed that the treatment of CRPC with TW was mainly associated with AGE-RAGE signaling pathway in diabetic complications, chemotactic-receptor activation, proteoglycans in cancer, microRNA Table S1: 51 bioactive components in Tripterygium wilfordii.

Mol.Coss90 Indexmapsine Geo. Geo. Geo. MOLCOS105 B1827-74-9 45.20 G.S. MOLCOS105 B1827-74-9 45.20 G.S. MOLCOS105 phramithm 2-on 45.20 G.S. MOLCOS105 Tipplatic 51.29 G.S. MOLCOS105 Tipplatic 51.29 G.S. MOLCOS105 Tipplatic 67.20 G.S. MOLCOS105 Tipplatic 67.20 G.S. MOLCOS105 Sphill-Straydrap (-4)pdraydrap (-4)pdray	MOL ID	Molecule Name	OB (%)	DL
MOL003192(+)Medionepinol di-Deate-Gybocyranolos, q.40.8040.80MOL003183(18,448,763)-fripticory-f	MOL000296	hederagenin	36.91	0.75
MCL003194 BIB27-74-9 45.42 0.53 MCL003185 REARF, 108/S-Paptrony-1-flyttorymethyl7-tiscorqu/sh-metholy-1.43, 10,101e trathylto-3H- phanattrans-2.cns 45.84 0.33 MCL003187 Trepholia 75.72 0.72 MCL003187 Trepholia 75.72 0.72 MCL003187 Trepholia 0.76 0.72 MCL003187 Trepholia 0.72 0.72 MCL003187 Spins-HerroryM-4 spins-hydroxy-1 beta 8 inpha-dimicotinoy-dihydro-agerufuran 0.72 0.72 MCL003187 Spins-HerroryM-4 spins-hydroxy-1 beta 8 inpha-dimicotinoy-dihydro-agerufuran 0.72 0.72 MCL003208 Calabiciumine 0.72 0.72 0.72 MCL003208 Calabiciumine 0.72 0.72 0.72 MCL003207 Calabiciumine add 0.72 0.72 0.72 MCL003217 Calabiciumine add 0.72 0.72 0.72 MCL003223 Trephorine add 0.72 0.72 0.72 MCL003224 Trephorine add 0.72 0.72 0.72 0.7	MOL003182	(+)-Medioresinol di-O-beta-D-glucopyranoside_qt	60.69	0.62
INDLODS Interfactor 48.44 0.38 MOLD03167 Teplate 612.20 0.68 MOLD031867 Teplator 612.20 0.72 MOLD03186 Teplator 85.66 0.72 MOLD03186 Teplator 85.66 0.72 MOLD03186 Teplator 85.66 0.72 MOLD03186 Teplator 85.66 0.74 MOLD03186 Teplator 85.66 0.74 MOLD03186 Salphatemzykt alphat-hydroxy-bental alphat-microtoxy-delnydro-agerufuran 85.26 0.74 MOLD03206 Celabachmine 77.41 0.33 0.83 MOLD03207 Celabachmine 85.74 0.84 MOLD03208 Celabachmine 85.81 0.38 MOLD03209 Celabachmine 95.84 0.76 MOLD03201 Teplatorinda 76.73 0.48 MOLD03221 Teplatorinda 77.41 0.38 MOLD03223 Teplatorinda 96.84 0.76 MOLD03231 Teplato	MOL003184	81827-74-9	45.42	0.53
MOL03917 inpola 61.20 0.61 MOL03018 Tipchkonalke 7872 0.72 MOL03180 Tipchkonalke 3660 0.72 MOL03192 Tiptpola 45.5 0.44 MOL03192 Tiptpola 45.5 0.44 MOL03196 Salpha-Berocyl-4 alpha-hydroxy-1 bela,8 alpha-dinicotincyl-dihydra-agarofuran 35.20 0.72 MOL03306 Carlin 77.41 0.33 MOL03306 Calalocinine 77.44 0.44 MOL03307 Calalocinine 30.18 0.82 MOL033210 Calalocinine 30.81 0.82 MOL033221 Calalocinine add 30.81 0.73 MOL033221 Inplatolinde 30.81 0.74 MOL033221 Inplatolinde 30.81 0.73 MOL033225 Inplatolinde 30.81 0.76 MOL033225 Tiplatolinde 30.81 0.76 MOL03325 Tiplatolinde 30.81 0.76 MOL03325 Tiplatolinde	MOL003185	(1R,4aR,10aS)-5-hydroxy-1-(hydroxymethyl)-7-isopropyl-8-methoxy-1,4a-dimethyl-4,9,10,10a-tetrahydro-3H- phenanthren-2-one	48.84	0.38
MOL039188 Tipplinoliais 78-72 72.72 MOL039189 WILFORLIDE A 672 MOL031990 Tipplicholiais 672 MOL031990 Tipplicholiais 674 MOL031990 Salpha Berrazyot 485.5 6.42 MOL031990 Salpha Berrazyot 485.5 0.72 MOL031990 Salpha Berrazyot 485.4 0.43 MOL031990 Salpha Berrazyot 483.4 0.33 MOL032200 Cellaturine 77.41 0.33 MOL032210 Cellaturine 68.4 0.47 MOL032210 Cellaturine 68.4 0.47 MOL032210 Cellaturine 68.4 0.47 MOL032211 Cellaturine 68.4 0.47 MOL032221 Tippideling A 0.40 40.4 MOL032231 Tippideling B 0.40 40.40 MOL032231 Tippideling B 0.40 40.40 MOL032323 Tippideling B 0.76 0.76 MOL032333	MOL003187	triptolide	51.29	0.68
MOL003189 WILFORLOE A 57.66 0.72 MOL003182 Triptorole 67.66 0.71 MOL003182 Triptorole 64.55 0.44 MOL003185 5.80hydroxy-7.(4-hydroxy-5-medhyl-cournarin-3)-cournarin 58.20hydroxy-7.(4-hydroxy-5-medhyl-cournarin-3)-cournarin 77.41 0.33 MOL003206 Canin 77.41 0.33 0.347 0.53 MOL0032010 Calaganine 30.18 0.82 0.44 MOL0032010 Calaganine 30.18 0.82 0.82 MOL003211 Iscoanthohumol 66.81 0.38 0.82 MOL003221 Iscoanthohumol 66.81 0.38 0.62 0.36 MOL003223 Triptoring B 0.47 0.72 0.76 MOL003224 Triptoring B1 0.42 0.36 0.49 MOL003235 Triptoring B1 0.47 0.76 MOL003236 Triptoring B1 0.47 0.76 MOL003237 Triptoring B1 0.47 0.76 MOL003238	MOL003188	Tripchlorolide	78.72	0.72
MOL003192 Triptorphenolide 0.7 MOL003196 Triptorphenolide 48.5 0.44 MOL003196 Sahab Berzol/a lapha Hydroxy-1 beta,8 alpha dinicotinoyi dinydro-agarofuran 67.86 0.44 MOL003196 Sa-Dirydroxy-7 (4-hydroxy-5-methyl-aounarin-3)-counarin 77.44 0.43 MOL003206 Calafurine 77.24 0.44 MOL003207 Calabaratina 63.47 0.59 MOL003208 Calabaratina 63.41 0.76 MOL003201 Calabaratina 63.41 0.76 MOL003221 Calabaratina 66.81 0.39 MOL003223 Triptorolide A 76.13 0.32 MOL003224 Triptorolide A 76.13 0.42 MOL003235 Triptorolide B 34.73 0.32 MOL003234 Triptorolide B 34.73 0.32 MOL003235 Triptorolide D 0.36 0.76 MOL003234 Triptorolide D 0.76 0.76 MOL003235 Triptorolide D2 0.33 0.67	MOL003189	WILFORLIDE A	35.66	0.72
MOL003196 Typepopenelide 44.5 0.44 MOL003196 Salpha-Benznyl-4 bein-Pydroxy-1 bein, Salpha-Genznyl- oumarin-3)-coumarin 61.25 0.54 MOL003206 Canin 77.41 0.33 MOL003206 Calulrum 77.41 0.33 MOL003207 Celationnine 83.47 0.59 MOL003208 Celationnine 63.14 0.52 MOL003210 Celationnine 63.14 0.67 MOL003221 Ispanine 30.18 0.38 MOL003223 Teptotohnine 65.81 0.37 MOL003224 Teptotohnine 65.81 0.87 MOL003225 Teptotohnine 76.13 0.49 MOL003224 Teptotohnine 30.40 0.76 MOL003235 Teptotohnine 30.50 0.84 MOL003236 Teptotohnine 30.36 0.89 MOL003237 Teptotohnine 30.36 0.81 MOL003238 Teptotohnine 30.37 0.87 MOL003235 Teptotohnine<	MOL003192	Triptonide	67.66	0.7
MOL003198 Spåln-ælmcoyf-4 alpha-ydroxy-1 beta,8 alpha-dinicetinny-ditiydro-agarofuran 95.2 0.72 MOL003190 S,8-Dhydroxy-7.(4+tydroxy-5-methyl-cournarin-3)-cournarin 61.85 0.54 MOL003208 Celefinine 77.41 0.33 MOL003209 Celefinine 30.47 0.58 MOL003210 Celefinine 30.48 0.82 MOL003221 Cellatocinnine 30.41 0.58 MOL003222 Salaznic add 0.68.11 0.38 MOL003221 Topidocinine 66.41 0.67 MOL003222 Salaznic add 76.13 0.49 MOL003224 Triptocinine B 44.33 0.22 MOL003231 Triptocinine B 44.02 0.38 MOL003233 Triptocinine B 0.38 0.89 MOL003234 Triptocinin B 0.76 0.40 MOL003235 Triptocinin D 33.81 0.89 MOL003236 Triptocinin D 33.81 0.80 MOL003236 Triptocinin D 33.81 0.81 <	MOL003196	Tryptophenolide	48.5	0.44
MQL003199 5.6-Ditydroxy-7-(4-tydroxy-6-methyl-coumarin-3)-coumarin 61.4 MQL003200 Celafurine 77.41 0.33 MQL003200 Celafurine 72.94 0.44 MQL0032010 Celafurine 83.47 0.59 MQL003217 Colapanine 83.47 0.59 MQL003217 Isolamine- 66.4 0.76 MQL003222 Salazinic acid 36.34 0.76 MQL003221 Tripdortine 76.13 0.49 MQL003225 Tripdortine 40.02 0.38 MQL003226 Tripdortine B1 40.02 0.38 MQL003231 Tripdortine B1 39.55 0.84 MQL003232 Tripdortine B1 39.55 0.84 MQL003233 Tripdortine B1 39.55 0.84 MQL003234 Tripdortine B1 39.55 0.84 MQL003235 Tripdortine B2 0.76 0.71 0.74 MQL003234 Tripdortine D2 39.38 0.69 MQL003235 Tripdortine D2	MOL003198	5 alpha-Benzoyl-4 alpha-hydroxy-1 beta,8 alpha-dinicotinoyl-dihydro-agarofuran	35.26	0.72
MOL003206 Calalucinine 77.44 0.33 MOL003208 Celalucinine 72.94 0.44 MOL003209 Celalucinine 38.47 0.58 MOL003210 Celasanthin 38.47 0.58 MOL003217 Isoaanthonumol 47.37 0.58 MOL003221 Stazinic acid 38.34 0.76 MOL003222 Stazinic acid 38.34 0.76 MOL003224 Tripicitorine 56.4 0.67 MOL003225 Tripicitorine 36.34 0.76 MOL003224 Tripicitorine 36.43 0.76 MOL003232 Tripicitorine 1 0.40 0.40 0.40 0.40 0.40 0.40 0.40 0.40 0.41 0.76 0.40 0.40 0.40 0.40 0.40 0.76 0.40 0.40 0.76 0.40 0.40 0.76 0.40 0.40 0.76 0.40 0.40 0.76 0.41 0.76 0.40 0.40 0.40 0.41	MOL003199	5,8-Dihydroxy-7-(4-hydroxy-5-methyl-coumarin-3)-coumarin	61.85	0.54
MOL03209 Celafurine 72.94 0.44 MOL002309 Celalacinnine 83.47 0.58 MOL002311 Celasanthin 47.37 0.58 MOL002311 celasanthin 47.37 0.58 MOL003217 Isoxanthohumol 56.81 0.39 MOL003224 Triptiotonide 66.4 0.67 MOL003255 Hypodiolide A 0.76 0.40 MOL003225 Triptiotonine B 34.73 0.32 MOL003231 Triptiotonin B 34.73 0.32 MOL003232 Triptiotonin B2 0.40 0.40 0.32 MOL003231 Triptiotonin B2 0.41 0.76 0.40 0.75 MOL003234 Triptiotonin C2 3.33 0.68 0.75 0.75 MOL003235 Triptiotonin F4 33.71 0.67 0.42 0.36 0.37 MOL003241 Triptiotonin F4 33.71 0.67 0.42 0.37 0.47 MOL0032425 Triptiotonin F4 33.71	MOL003206	Canin	77.41	0.33
MOL003209 Celalacinnine 83.47 0.59 MOL003211 Celapanine 30.18 0.82 MOL003217 Isoxanthohumol 47.37 0.58 MOL003217 Isoxanthohumol 56.81 0.39 MOL003225 Salazine acid 36.44 0.67 MOL00325 Tripdiofinde 56.44 0.67 MOL00325 Tripdiofinde 36.43 0.76 MOL003225 Tripdioferdin B1 38.73 0.32 MOL003232 Tripdioferdin B1 38.55 0.84 MOL003233 Tripdioferdin B1 38.55 0.84 MOL003234 Tripdioferdin C2 30.16 0.76 MOL003235 Tripdioferdin D2 30.38 0.86 MOL003236 Tripdioferdin P2 33.62 0.87 MOL003237 Tripdioferdin F2 33.62 0.87 MOL003238 Tripdioferdin F4 33.91 0.86 MOL003244 Tripdioferdin F4 33.87 0.82 MOL003244 Tripdioferdin F4	MOL003208	Celafurine	72.94	0.44
MOL03210 Celapanine 30.18 0.82 MOL003211 Celapanine 47.37 0.85 MOL003222 Salazinic acid 36.34 0.76 MOL003224 Triptolotilide A 36.34 0.76 MOL003225 Salazinic acid 36.34 0.76 MOL003226 Triptolotile A 76.13 0.49 MOL003227 Triptolethypenic acid B 34.73 0.32 MOL003231 Triptolotile Pa 34.73 0.32 MOL003232 Triptolotile Pa 34.73 0.32 MOL003233 Triptolotile Pa 34.73 0.32 MOL003233 Triptolotile Pa 30.66 0.76 MOL003234 Triptolotile Pa 30.16 0.76 MOL003235 Triptolotile Pa 33.81 0.67 MOL003236 Triptolotile Pa 33.82 0.67 MOL003241 Triptolotile Pa 33.82 0.67 MOL003242 Triptolotile Pa 33.82 0.67 MOL003245 Triptolotile Pa </td <td>MOL003209</td> <td>Celallocinnine</td> <td>83.47</td> <td>0.59</td>	MOL003209	Celallocinnine	83.47	0.59
MOL03211 Celaxanthniumol 47.37 0.58 MOL003271 Isoxanthniumol 56.81 0.39 MOL003222 Salazine acid 56.4 0.67 MOL003224 Tipidiotalnide 56.4 0.67 MOL003225 Hypodiolide A 76.13 0.49 MOL003231 Tipitofaltepenic acid B 40.02 0.36 MOL003232 Tipitofarlin B1 38.55 0.84 MOL003234 Tipitofarlin B1 39.55 0.84 MOL003235 Tipitofarlin C2 30.16 0.76 MOL003234 Tipitofardin C2 30.38 0.69 MOL003235 Tipitofardin C2 30.38 0.69 MOL003236 Tipitofardin F1 33.91 0.6 MOL003238 Tipitofardin F1 33.62 0.67 MOL003241 Tipitofardin F2 30.38 0.89 MOL003242 Tipitofardin F4 31.37 0.67 MOL003241 Tipitofardin F2 32.8 0.68 MOL003245 Tipitofardin F2	MOL003210	Celapanine	30.18	0.82
MOL003217 Boxanthohumol 56.81 0.39 MOL003222 Salazini acid 38.34 0.76 MOL003225 Salazini acid 56.4 0.67 MOL003226 Tipolotolnide 56.4 0.67 MOL003227 Tipilotini B 34.73 0.32 MOL003231 Tiplotordin B1 39.55 0.84 MOL003232 Tiplotordin B1 39.55 0.84 MOL003231 Tiplotordin B2 107.71 0.76 MOL003232 Tiplotordin B2 107.71 0.76 MOL003234 Tiplotordin D1 32 0.75 MOL003235 Tiplotordin D1 32 0.75 MOL003236 Tiplotordin D1 32 0.75 MOL003237 Tiplotordin F1 33.31 0.67 MOL003238 Tiplotordin F2 30.78 0.47 MOL003241 Tiplotordin F4 31.37 0.67 MOL003242 Tiplotordin F4 31.37 0.67 MOL003242 Tiplotordin F4 31.37	MOL003211	Celaxanthin	47.37	0.58
MOL003222 Salazinic acid 36.34 0.76 MOL003224 Tripcinolnide 56.4 0.67 MOL003229 Tripcinolnide 34.73 0.32 MOL003221 Tripcinolni B 34.73 0.32 MOL003231 Tripcinolni B1 40.02 0.36 MOL003233 Tripcinordin B2 107.71 0.76 MOL003234 Tripcinordin B2 0.07 0.76 MOL003235 Tripcinordin B2 30.16 0.76 MOL003236 Tripcinordin D2 30.38 0.69 MOL003236 Tripcinordin D2 30.31 0.6 MOL003236 Tripcinordin P2 33.81 0.6 MOL003237 Tripcinordin P2 33.71 0.67 MOL003240 Tripcinordin P4 31.7 0.67 MOL003241 Tripcinordin P4 31.7 0.67 MOL003242 Tripcinordin P4 31.7 0.67 MOL003245 Tripcinordin P4 31.7 0.67 MOL003245 Tripcinordin P4	MOL003217	Isoxanthohumol	56.81	0.39
MOL003224 Triptiotolnide 56.4 0.67 MOL003225 Hypodolide A 76.13 0.49 MOL003221 Triptiotifrepenic acid B 34.73 0.32 MOL003222 Triptiotifrepenic acid B 39.55 0.34 MOL003231 Triptotifrepenic acid B 39.55 0.34 MOL003232 Triptotorin B1 39.55 0.34 MOL003233 Triptoforin C2 30.16 0.76 MOL003235 Triptoforin C2 30.38 0.69 MOL003236 Triptofordin P1 33.31 0.67 MOL003238 Triptofordin F2 33.81 0.67 MOL003238 Triptofordin F2 33.81 0.67 MOL003241 Triptofordin F4 31.37 0.67 MOL003242 Triptofordin F2 33.81 0.67 MOL003241 Triptofordin F4 31.37 0.67 MOL003244 Triptofordin F4 34.71 0.78 MOL03245 Triptofordin F4 36.81 0.68 MOL03245	MOL003222	Salazinic acid	36.34	0.76
MOL003225 Hypodiolide A 76.13 0.49 MOL003220 Triptoline B 44.73 0.32 MOL003231 Triptoliterpenic acid B 40.02 0.36 MOL003232 Triptolorcin B1 93.55 0.84 MOL003233 Triptolorcin B2 107.71 0.76 MOL003234 Triptolorcin C2 30.16 0.76 MOL003235 Triptolorcin D1 32 0.75 MOL003236 Triptolorcin D2 30.38 0.69 MOL003238 Triptolorcin D2 33.81 0.6 MOL003238 Triptolorcin F1 33.91 0.6 MOL003241 Triptolorcin F2 33.62 0.67 MOL003242 Triptolorcin F4 31.37 0.67 MOL003241 Triptolorcin P4 31.37 0.67 MOL003242 Triptolorcin P4 31.37 0.67 MOL003245 Triptonoterpenic acid 42.56 0.39 MOL003245 Triptonoterpenic acid 42.56 0.39 MOL003245 T	MOL003224	Tripdiotolnide	56.4	0.67
MOL003229 Triptini B 34.73 0.32 MOL003311 Triptoditerpenic acid B 40.02 0.36 MOL003232 Triptofordin B1 39.55 0.84 MOL003333 Triptofordin B1 0.76 MOL003234 Triptofordin D2 30.16 0.76 MOL003235 Triptofordin D1 32 0.75 MOL003236 Triptofordin D2 30.38 0.69 MOL003236 Triptofordin F1 33.91 0.6 MOL003237 Triptofordin F2 33.82 0.67 MOL003241 Triptofordin F4 31.37 0.67 MOL003242 Triptofordin F4 31.37 0.67 MOL003242 Triptofordine A2 0.78 0.47 MOL003244 Triptofordine A2 0.68 0.68 MOL003245 Triptofordine A2 0.28 0.39 MOL003246 Triptofordine A2 0.28 0.39 MOL003245 Triptofordine A2 0.29 0.81 0.75 MOL003245 Triptofordine	MOL003225	Hypodiolide A	76.13	0.49
MOL003231 Triptoditerpenic acid B 40.02 0.36 MOL003232 Triptofordin B1 39.55 0.84 MOL003233 Triptofordin B2 107.71 0.76 MOL003234 Triptofordin C2 30.68 0.76 MOL003235 Triptofordin D1 32 0.75 MOL003236 Triptofordin D1 33.81 0.69 MOL003238 Triptofordin F1 33.81 0.67 MOL0032341 Triptofordin F2 33.62 0.67 MOL003242 Triptofordin F4 31.37 0.67 MOL003244 Triptofordin F4 31.37 0.67 MOL003245 Triptofordin F4 31.37 0.67 MOL003244 Triptoinde 68.45 0.68 MOL003245 Triptoinderpenic acid 42.56 0.39 MOL003245 Triptoinderpenic acid 32.19 0.63 MOL003276 Vietorpenic acid 32.19 0.63 MOL003278 Selsepermic acid 32.19 0.63 MOL003279	MOL003229	Triptinin B	34.73	0.32
MOL003232 Triptofordin B1 39.55 0.84 MOL003233 Triptofordin B2 107.71 0.76 MOL003234 Triptofordin C2 30.16 0.76 MOL003235 Triptofordin D1 32 0.57 MOL003235 Triptofordin D1 33.81 0.69 MOL003238 Triptofordin D2 33.81 0.67 MOL003239 Triptofordin F1 33.82 0.67 MOL003241 Triptofordin F4 33.82 0.67 MOL003242 Triptofordin F4 30.78 0.47 MOL003241 Triptofordin F4 30.78 0.47 MOL003244 Triptofordin F4 68.45 0.68 MOL03244 Triptonotife Pene 48.57 0.28 MOL03257 Triptonotiferpene 48.57 0.28 MOL03267 Wilformine 46.32 0.2 MOL03278 salaspermic acid 32.19 0.63 MOL003278 salaspermic acid 36.81 0.75 MOL003280 TRIPTONOLIDE	MOL003231	Triptoditerpenic acid B	40.02	0.36
MOL003233 Triptofordin B2 107.71 0.76 MOL003234 Triptofordin C2 30.16 0.76 MOL003235 Triptofordin D1 30.38 0.69 MOL003238 Triptofordin D2 30.38 0.69 MOL003239 Triptofordin F1 33.31 0.6 MOL003234 Triptofordin F2 33.62 0.67 MOL003241 Triptofordin F4 33.7 0.67 MOL003242 Triptofordin F4 33.7 0.67 MOL003241 Triptofordin F4 31.37 0.67 MOL003242 Triptofordin F4 30.78 0.47 MOL003245 TriptofordineA2 0.28 0.39 MOL003245 Triptofordinpene 48.57 0.28 MOL003265 Triptonoterpene 46.32 0.2 MOL003267 salaspermic acid 32.19 0.63 MOL003279 salaspermic acid 32.19 0.63 MOL003280 TRIPTONOLIDE 49.51 0.49 MOL000328 beta-sitosterol<	MOL003232	Triptofordin B1	39.55	0.84
MOL003234 Triptofordin C2 30.16 0.76 MOL003235 Triptofordin D1 32 0.75 MOL003236 Triptofordin D2 30.38 0.69 MOL003233 Triptofordin F1 33.91 0.67 MOL003234 Triptofordin F2 33.91 0.67 MOL003235 Triptofordin F4 33.91 0.67 MOL003242 Triptofordin F4 33.77 0.67 MOL003242 Triptofordin F4 30.78 0.47 MOL003244 Triptonoditerpenic acid 48.57 0.58 MOL003245 Triptonoditerpene 48.57 0.28 MOL003248 Triptonoditerpene 46.32 0.2 MOL003257 Wiformine 36.91 0.75 MOL00327 salaspermic acid 32.19 0.63 MOL00327 salaspermic acid 36.91 0.75 MOL00327 salaspermic acid 36.91 0.75 MOL00329 TRIPTONOLIDE 36.91 0.75 MOL000321 Mairin	MOL003233	Triptofordin B2	107.71	0.76
MOL03235 Triptofordin D1 32 0.75 MOL03236 Triptofordin D2 30.38 0.69 MOL03238 Triptofordin F1 33.31 0.6 MOL03239 Triptofordin F2 33.62 0.67 MOL03241 Triptofordin F4 31.37 0.67 MOL03242 Triptofordin F4 30.78 0.47 MOL03243 Triptofordin F2 30.78 0.47 MOL03244 Triptofordin F4 30.78 0.47 MOL03245 Triptofordin F2 0.87 0.88 MOL03245 Triptonoide 68.45 0.88 MOL03266 21+Hydroxy-30-norhopan-22-one 44.57 0.28 MOL03278 salaspermic acid 32.19 0.63 MOL03279 9964-86-7 75.23 0.66 MOL003280 TRIPTONOLIDE 49.51 0.49 MOL003281 Taiptoroid 45.53 0.78 MOL003284 beta-sitosterol 36.91 0.75 MOL000012 kaempferol 55.38	MOL003234	Triptofordin C2	30.16	0.76
MOL003236 Triptofordin D2 0.99 MOL003238 Triptofordin F1 33.91 0.6 MOL003239 Triptofordin F2 33.62 0.67 MOL003241 Triptofordin F4 33.62 0.67 MOL003242 Triptofordin F4 30.78 0.47 MOL003244 Triptofordin F4 68.45 0.68 MOL003244 Triptonoditerpenic acid 42.56 0.39 MOL003250 Triptonoditerpenic acid 44.57 0.28 MOL003262 21-Hydroxy-30-norhopan-22-one 34.11 0.77 MOL003279 salaspermic acid 46.32 0.2 MOL003279 salaspermic acid 32.19 0.63 MOL003279 salaspermic acid 36.91 0.75 MOL003280 TRIPTONOLIDE 49.51 0.49 MOL000328 tea-sitosterol 36.91 0.75 MOL000049 Stigmasterol 43.83 0.76 MOL000284 40957-99-1 57.2 0.52 MOL003283 (2R,3R,4S)-4-(4-h	MOL003235	Triptofordin D1	32	0.75
MOL003238 Triptofordin F1 33.91 0.6 MOL003239 Triptofordin F2 33.62 0.67 MOL003241 Triptofordin F4 31.37 0.67 MOL003242 Triptofordinine A2 30.78 0.47 MOL003244 Triptonde 68.45 0.68 MOL003245 Triptonolerpene 48.57 0.28 MOL003266 21-Hydroxy-30-norhopan-22-one 34.11 0.77 MOL003267 Wilformine 46.32 0.2 MOL003267 Wilformine 46.32 0.2 MOL003278 salaspermic acid 32.19 0.63 MOL003280 TRIPTONOLIDE 49.51 0.49 MOL003280 TRIPTONOLIDE 49.51 0.49 MOL000328 beta-sitosterol 36.91 0.75 MOL000328 tigmasterol 43.83 0.76 MOL000422 kaempferol 41.88 0.24 MOL000428 (2R,3R,4S)-4(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 66.51 0.39	MOL003236	Triptofordin D2	30.38	0.69
MOL003299 Triptofordin F2 0.67 MOL003241 Triptofordin F4 31.37 0.67 MOL003242 Triptofordin F4 30.78 0.47 MOL003242 Triptofordinine A2 30.78 0.47 MOL003244 Triptonoditerpenic acid 68.45 0.68 MOL003265 Triptonoditerpenic acid 48.57 0.28 MOL003266 1-Hydroxy-30-northopan-22-one 34.11 0.77 MOL003267 Wilformine 46.32 0.2 MOL003278 salaspermic acid 32.19 0.63 MOL003280 TRIPTONOLIDE 49.51 0.49 MOL003280 TRIPTONOLIDE 49.51 0.49 MOL0003280 TRIPTONOLIDE 43.83 0.76 MOL000422 kaempferol 43.83 0.76 MOL000422 kaempferol 43.83 0.76 MOL000428 QE,38,4S)-4(4-hydroxy-3-methoxy-2,3-dimethylo1-tertalin-6-ol 66.51 0.39 MOL004443 Zhebeiresinol 57.2 0.62 MOL00328 </td <td>MOL003238</td> <td>Triptofordin F1</td> <td>33.91</td> <td>0.6</td>	MOL003238	Triptofordin F1	33.91	0.6
MOL003241 Triptofordin F4 31.37 0.67 MOL003242 Triptofordinine A2 30.78 0.47 MOL003244 Triptonide 68.45 0.68 MOL003245 Triptonoditerpenic acid 42.56 0.39 MOL003248 Triptonoterpene 48.57 0.28 MOL003266 21-Hydroxy-30-norhopan-22-one 34.11 0.77 MOL003267 Wilformine 46.32 0.2 MOL003278 salaspernic acid 32.19 0.63 MOL003279 9664-86-7 0.66 0.49 MOL003280 TRIPTONOLIDE 0.61 0.49 MOL003280 TRIPTONOLIDE 36.91 0.75 MOL000422 kaempferol 44.38 0.24 MOL000422 kaempferol 41.88 0.24 MOL003283 CR,RA,S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 65.51 0.39 MOL0004443 Zheberiesinol 58.72 0.62 MOL003284 nobiletin 61.67 0.52	MOL003239	Triptofordin F2	33.62	0.67
MOL003242 Triptofordinine A2 30.78 0.47 MOL003244 Triptonide 68.45 0.68 MOL003245 Triptonoditerpenic acid 42.58 0.39 MOL003248 Triptonoterpene 48.57 0.28 MOL003266 21-Hydroxy-30-norhopan-22-one 34.11 0.77 MOL003267 Wilformine 46.32 0.2 MOL003278 salaspermic acid 32.19 0.63 MOL003279 9694-86-7 0.45 0.49 MOL003280 TRIPTONOLIDE 49.51 0.49 MOL003280 TRIPTONOLIDE 49.51 0.49 MOL0003280 genyferol 36.91 0.75 MOL000422 kaempferol 44.88 0.24 MOL003283 (2R,3R,4S)-4(-4hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 41.88 0.24 MOL003283 (2R,3R,4S)-4(-4hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 66.51 0.39 MOL003284 robiletin 58.72 0.62 0.52 MOL003284	MOL003241	Triptofordin F4	31.37	0.67
MOL003244 Triptonide 68.45 0.68 MOL003245 Triptonoditerpenic acid 42.56 0.39 MOL003248 Triptonoterpene 48.57 0.28 MOL003266 21-Hydroxy-30-norhopan-22-one 34.11 0.77 MOL003267 Wilformine 46.32 0.2 MOL003278 salaspermic acid 32.19 0.63 MOL003279 99694-86-7 75.23 0.66 MOL003280 TRIPTONOLIDE 49.51 0.49 MOL0003280 beta-sitosterol 36.91 0.75 MOL0002011 Mairin 55.38 0.78 MOL000422 kaempferol 41.88 0.24 MOL000423 kaempferol 41.88 0.24 MOL000424 Apebeiresinol 55.28 0.78 MOL000258 d0957-99-1 57.2 0.62 MOL000443 Zhebeiresinol 65.51 0.39 MOL004443 Zhebeiresinol 55.28 0.51 MOL005258 nobiletin 65.12	MOL003242	Triptofordinine A2	30.78	0.47
MOL003245 Triptonoditerpenic acid 42.56 0.39 MOL003248 Triptonoterpene 48.57 0.28 MOL003266 21-Hydroxy-30-norhopan-22-one 34.11 0.77 MOL003267 Wilformine 46.32 0.2 MOL003278 salaspernic acid 32.19 0.63 MOL003279 99694-86-7 75.23 0.66 MOL003280 TRIPTONOLIDE 49.51 0.49 MOL00358 beta-sitosterol 36.91 0.75 MOL000211 Mairin 55.38 0.78 MOL000422 kaempferol 41.88 0.24 MOL000449 Stigmasterol 43.83 0.76 MOL003283 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 66.51 0.39 MOL003283 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 66.51 0.39 MOL003283 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 66.51 0.39 MOL003283 robletin 61.67 0.52 <	MOL003244	Triptonide	68.45	0.68
MOL003248 Triptonoterpene 48.57 0.28 MOL003266 21-Hydrxxy-30-norhopan-22-one 34.11 0.77 MOL003267 Wilformine 46.32 0.2 MOL003278 salaspernic acid 32.19 0.63 MOL003279 99694-86-7 75.23 0.66 MOL003280 TRIPTONOLIDE 49.51 0.49 MOL000358 beta-sitosterol 36.91 0.75 MOL0000211 Mairin 55.38 0.78 MOL000422 kaempferol 44.88 0.24 MOL0002058 40957-99-1 57.2 0.62 MOL0002058 40957-99-1 57.2 0.62 MOL0002058 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 66.51 0.39 MOL0002058 nobiletin 58.72 0.19 MOL0005828 nobiletin 58.02 0.52 MOL007535 (5S,8S,9S,10R,13R,14S,17R)-17-(TH,4R)-4-ethyl-1,5-dimethylhexyl-10,13-dimethyl-2,4,5,7,8,9,11,12,14,15,16,16,7 33.12 0.79 MOL0007535 (5S,8S	MOL003245	Triptonoditerpenic acid	42.56	0.39
MOL003266 21-Hydroxy-30-norhopan-22-one 34.11 0.77 MOL003267 Wilformine 46.32 0.2 MOL003278 salaspermic acid 32.19 0.63 MOL003279 99694-86-7 75.23 0.66 MOL003280 TRIPTONOLIDE 49.51 0.49 MOL00358 beta-sitosterol 36.91 0.75 MOL000358 beta-sitosterol 36.91 0.75 MOL000211 Mairin 55.38 0.78 MOL000422 kaempferol 41.88 0.24 MOL0002058 40957-99-1 57.2 0.62 MOL0002058 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 66.51 0.39 MOL002058 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 58.72 0.62 MOL003283 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 66.51 0.39 MOL003283 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 58.72 0.19 MOL005828 nobiletin	MOL003248	Triptonoterpene	48.57	0.28
MOL003267 Wilformine 46.32 0.2 MOL003278 salaspermic acid 32.19 0.63 MOL003279 99694-86-7 75.23 0.66 MOL003280 TRIPTONOLIDE 49.51 0.49 MOL000358 beta-sitosterol 36.91 0.75 MOL000358 beta-sitosterol 36.91 0.75 MOL000211 Mairin 55.38 0.78 MOL000422 kaempferol 41.88 0.24 MOL000423 kaempforol 43.83 0.76 MOL0002058 40957-99-1 57.2 0.62 MOL0002058 40957-99-1 57.2 0.62 MOL0002058 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 66.51 0.39 MOL002058 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 66.51 0.39 MOL0005828 nobiletin 61.67 0.52 0.52 MOL007535 (5S,8S,010R,13R,17R,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethylp-24,57,8,9,111,2,14,15,16,17- dodecahydro-1H-cyclopenta[a]phenanthrene-3,6-dione <t< td=""><td>MOL003266</td><td>21-Hydroxy-30-norhopan-22-one</td><td>34.11</td><td>0.77</td></t<>	MOL003266	21-Hydroxy-30-norhopan-22-one	34.11	0.77
MOL003278 salaspernic acid 32.19 0.63 MOL003279 99694-86-7 75.23 0.66 MOL003280 TRIPTONOLIDE 49.51 0.49 MOL00358 beta-sitosterol 36.91 0.75 MOL000211 Mairin 55.38 0.78 MOL000422 kaempferol 41.88 0.24 MOL000238 Stigmasterol 43.83 0.76 MOL000420 kaempferol 43.83 0.76 MOL000238 2(R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylo1-tetralin-6-ol 66.51 0.39 MOL002058 40957-99-1 58.72 0.162 MOL002058 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylo1-tetralin-6-ol 66.51 0.39 MOL002058 abletin 58.72 0.19 MOL00358 nobiletin 61.67 0.52 MOL007415 [(ZS)-2-[([ZS)-2-(benzoylamino)-3- phenylpropanoyl] amino]-3-phenylpropyl] acetate 58.02 0.52 MOL007535 (5S.8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-2,4,5,7,8,9,11,12,14,15,16,17-<	MOL003267	Wilformine	46.32	0.2
MOL003279 99694-86-7 75.23 0.66 MOL003280 TRIPTONOLIDE 0.49 0.49 MOL00358 beta-sitosterol 36.91 0.75 MOL000211 Mairin 55.38 0.78 MOL000422 kaempferol 41.88 0.24 MOL000423 stigmasterol 43.83 0.76 MOL000584 40957-99-1 57.2 0.62 MOL0002058 40957-99-1 57.2 0.62 MOL0002058 40957-99-1 58.72 0.19 MOL0002058 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 66.51 0.39 MOL0002058 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 66.51 0.39 MOL002058 robiletin 61.67 0.52 0.52 MOL005828 nobiletin 61.67 0.52 MOL007415 [(2S)-2-[[(2S)-2-(benzoylamino)-3- phenylpropanoyl] amino]-3-phenylpropyl] acetate 58.02 0.52 MOL007535 (5S,8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-2,4,5,7,8,9,	MOL003278	salaspermic acid	32.19	0.63
MOL003280 TRIPTONOLIDE 49.51 0.49 MOL00358 beta-sitosterol 36.91 0.75 MOL000211 Mairin 55.38 0.78 MOL000422 kaempferol 41.88 0.24 MOL000458 Stigmasterol 43.83 0.76 MOL0002058 40957-99-1 57.2 0.62 MOL003283 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 66.51 0.39 MOL004433 Zhebeiresinol 58.72 0.19 MOL005828 nobiletin 61.67 0.52 MOL007415 [(2S)-2-[([2S)-2-(benzoylamino)-3-phenylpropanoyl] amino]-3-phenylpropyl] acetate 58.02 0.52 MOL007415 [(2S)-2-[(2S)-2-(benzoylamino)-3-phenylpropanoyl] amino]-3-phenylpropyl] acetate 58.02 0.52 MOL007415 [(2S)-2-[(2S)-2-(benzoylamino)-3-phenylpropanoyl] amino]-3-phenylpropyl] acetate 58.02 0.52 MOL007535 [5S,8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-2,4,5,7,8,9,11,12,14,15,16,17* 33.12 0.79 MOL007536 [3'-bis-(3,4-dihydro-4-hydroxy-6-methoxy)-2H-1-benzopyran <td>MOL003279</td> <td>99694-86-7</td> <td>75.23</td> <td>0.66</td>	MOL003279	99694-86-7	75.23	0.66
MOL000358 beta-sitosterol 36.91 0.75 MOL000211 Mairin 55.38 0.78 MOL000422 kaempferol 41.88 0.24 MOL000449 Stigmasterol 43.83 0.76 MOL00258 40957-99-1 57.2 0.62 MOL003283 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 66.51 0.39 MOL003283 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 66.51 0.39 MOL003283 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 66.51 0.39 MOL003283 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 58.72 0.62 MOL003283 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 58.72 0.19 MOL003284 nobiletin 58.72 0.52 0.52 MOL007415 [(2S)-2-[((2S)-2-(benzoylamino)-3- phenylpropanoyl] anino]-3-phenylpropyl] acetate 58.02 0.52 MOL007535 [5S,8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-2,4,5,7,8,9,11,12,14,15,16,17- dodecahydro-	MOL003280	TRIPTONOLIDE	49.51	0.49
MOL000211 Mairin 55.38 0.78 MOL000422 kaempferol 41.88 0.24 MOL000449 Stigmasterol 43.83 0.76 MOL000258 40957-99-1 57.2 0.62 MOL003283 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 66.51 0.39 MOL004443 Zhebeiresinol 66.51 0.52 MOL005828 nobiletin 61.67 0.52 MOL007415 [(2S)-2-[([2S)-2-(benzoylamino)-3- phenylpropanoyl] amino]-3-phenylpropyl] acetate 58.02 0.52 MOL007535 \$5,8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-2,4,5,7,8,9,11,12,14,15,16,17- 33.12 0.79 MOL007535 \$5,3S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-2,4,5,7,8,9,11,12,14,15,16,17- 33.12 0.79 MOL007535 \$3,3-bis-(3,4-dihydro-4-hydroxy-6-methoxy)-2H-1-benzopyran 52.11 0.54 MOL011169 Peroxyergosterol 44.39 0.82	MOL000358	beta-sitosterol	36.91	0.75
MOL000422 kaempferol 41.88 0.24 MOL000449 Stigmasterol 43.83 0.76 MOL002058 40957-99-1 57.2 0.62 MOL003283 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 66.51 0.39 MOL004443 Zhebeiresinol 66.51 0.39 MOL005828 nobiletin 61.67 0.52 MOL007415 [(2S)-2-[([2S)-2-(benzoylamino)-3- phenylpropanoyl] amino]-3-phenylpropyl] acetate 58.02 0.52 MOL007535 (5S,8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-2,4,5,7,8,9,11,12,14,15,16,17- 33.12 0.79 MOL007535 (5S,8S,9S,10R,13R,14S,07R)-4-thyl-1,5-dimethylhexyl]-10,13-dimethyl-2,4,5,7,8,9,11,12,14,15,16,17- 33.12 0.79 MOL007535 (5S,8S,9S,10R,13R,14S,07R)-47-[(1R,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-2,4,5,7,8,9,11,12,14,15,16,17- 33.12 0.79 MOL007535 (5S,8S,9S,10R,13R,14S,07R)-47-[(1R,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-2,4,5,7,8,9,11,12,14,15,16,17- 33.12 0.79 MOL009386 3,3-bis-(3,4-dihydro-4-hydroxy-6-methoxy)-2H-1-benzopyran 52.11 0.54	MOL000211	Mairin	55.38	0.78
MOL000449 Stigmasterol 43.83 0.76 MOL002058 40957-99-1 57.2 0.62 MOL003283 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 66.51 0.39 MOL004443 Zhebeiresinol 66.51 0.19 MOL005828 nobiletin 61.67 0.52 MOL007415 [(2S)-2-[((2S)-2-(benzoylamino)-3- phenylpropanoyl] amino]-3-phenylpropyl] acetate 58.02 0.52 MOL007535 [SS,8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-2,4,5,7,8,9,11,12,14,15,16,17- 33.12 0.79 MOL007535 [SS,8S,9S,10R,13R,14S,07R)-4-thylory-2H-1-benzopyran 52.11 0.54 MOL009386 3,3'-bis-(3,4-dihydro-4-hydroxy-6-methoxy)-2H-1-benzopyran 52.11 0.54 MOL011169 Peroxyergosterol 44.39 0.82	MOL000422	kaempferol	41.88	0.24
MOL002058 40957-99-1 57.2 0.62 MOL003283 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 66.51 0.39 MOL004443 Zhebeiresinol 58.72 0.19 MOL005828 nobiletin 61.67 0.52 MOL007415 [(2S)-2-[[(2S)-2-(benzoylamino)-3- phenylpropanoyl] amino]-3-phenylpropyl] acetate 58.02 0.52 MOL007535 [5S,8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-2,4,5,7,8,9,11,12,14,15,16,17- 33.12 0.79 MOL007535 [5S,8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,benzopyran 52.11 0.54 MOL007536 3,3'-bis-(3,4-dihydro-4-hydroxy-6-methoxy)-2H-1-benzopyran 52.11 0.54 MOL011169 Peroxyergosterol 44.39 0.82	MOL000449	Stigmasterol	43.83	0.76
MOL003283 (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol 66.51 0.39 MOL004443 Zhebeiresinol 58.72 0.19 MOL005828 nobiletin 61.67 0.52 MOL007415 [(2S)-2-[[(2S)-2-(benzoylamino)-3- phenylpropanoyl] amino]-3-phenylpropyl] acetate 58.02 0.52 MOL007535 \$5,8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-2,4,5,7,8,9,11,12,14,15,16,17- 33.12 0.79 MOL009386 3,3'-bis-(3,4-dihydro-4-hydroxy-6-methoxy)-2H-1-benzopyran 52.11 0.54 MOL011169 Peroxyergosterol 44.39 0.82	MOL002058	40957-99-1	57.2	0.62
MOL004443 Zhebeiresinol 58.72 0.19 MOL005828 nobiletin 61.67 0.52 MOL007415 [(2S)-2-[[(2S)-2-(benzoylamino)-3- phenylpropanoyl] amino]-3-phenylpropyl] acetate 58.02 0.52 MOL007535 (5S,8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-2,4,5,7,8,9,11,12,14,15,16,17- dodecahydro-1H-cyclopenta[a]phenanthrene-3,6-dione 33.12 0.79 MOL009386 3,3'-bis-(3,4-dihydro-4-hydroxy-6-methoxy)-2H-1-benzopyran 52.11 0.54 MOL011169 Peroxyergosterol 44.39 0.82	MOL003283	(2R.3R.4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2.3-dimethylol-tetralin-6-ol	66.51	0.39
MOL005828 nobiletin 61.67 0.52 MOL007415 [(2S)-2-[((2S)-2-(benzoylamino)-3- phenylpropanoyl] amino]-3-phenylpropyl] acetate 58.02 0.52 MOL007535 (5S,8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-2,4,5,7,8,9,11,12,14,15,16,17- dodecahydro-1H-cyclopenta[a]phenanthrene-3,6-dione 33.12 0.79 MOL009386 3,3'-bis-(3,4-dihydro-4-hydroxy-6-methoxy)-2H-1-benzopyran 52.11 0.54 MOL011169 Peroxyergosterol 44.39 0.82	MOL004443	Zhebeiresinol	58.72	0.19
MOL007415 [(2S)-2-[[(2S)-2-(benzoylamino)-3- phenylpropanoyl] amino]-3-phenylpropyl] acetate 58.02 0.52 MOL007535 (5S,8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-2,4,5,7,8,9,11,12,14,15,16,17- dodecahydro-1H-cyclopenta[a]phenanthrene-3,6-dione 0.79 33.12 0.79 MOL009386 3,3'-bis-(3,4-dihydro-4-hydroxy-6-methoxy)-2H-1-benzopyran 52.11 0.54 MOL011169 Peroxyergosterol 44.39 0.82	MOL005828	nobiletin	61.67	0.52
MOL007535 (55,88,98,10R,13R,148,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-2,4,5,7,8,9,11,12,14,15,16,17- dodecahydro-1H-cyclopenta[a]phenanthrene-3,6-dione 0.79 MOL009386 3,3'-bis-(3,4-dihydro-4-hydroxy-6-methoxy)-2H-1-benzopyran 52.11 0.54 MOL011169 Peroxyergosterol 44.39 0.82	MQL007415	[(2S)-2-[[(2S)-2-(benzovlamino)-3- phenylpropanovl] amino]-3-phenylpropyl] acetate	58.02	0.52
MOL009386 3,3'-bis-(3,4-dihydro-4-hydroxy-6-methoxy)-2H-1-benzopyran 52.11 0.54 MOL011169 Peroxyergosterol 44.39 0.82	MOL007535	(5S,8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-2,4,5,7,8,9,11,12,14,15,16,17- dodecahydro-1H-cyclopentalalbhenanthrene-3 6-dione	33.12	0.79
MOL011169 Peroxyergosterol 44.39 0.82	MOL009386	3,3'-bis-(3,4-dihydro-4-hydroxy-6-methoxy)-2H-1-benzopyran	52.11	0.54
	MOL011169	Peroxyergosterol	44.39	0.82



in cancer, endocrine resistance, p53 signaling pathway, estrogen signaling pathway, PI3K-Akt signaling pathway, IL-17 signaling pathway, JAK-STAT signaling pathway, HIF-1 signaling pathway, and TNF signaling pathway. The GO/KEGG enrichment analysis were displayed in Figure 7. The above biological processes were closely related to the development of CRPC, suggesting that TW can treat CRPC through a multi-targets and multi-pathways approach.

Construction of the component-target-signaling pathway network

The relationships between active components, intersectional targets, and major signaling pathways in the mechanism of TW action for CRPC were shown in Figure 8. From the network, we found that active components of TW acted on 38 intersectional targets through multiple signaling pathways for the treatment of CRPC. The active components with network neutrality values ≥ 10 were kaempferol,

triptolide, and nobiletin, suggesting these components were the key components of TW for the treatment in CRPC. The targets with network neutrality values ≥ 10 were PTGS2, NCOA2, ADRB2, AKT1, BCL2, TP53, CASP3 and STAT3, suggesting that these targets were the core targets of TW for the treatment of CRPC. The top pathways in the network neutrality values were MicroRNAs in cancer, Chemical carcinogenesis-receptor activation, and Proteoglycans in cancer, suggesting that these pathways were the core pathways of TW for the treatment of CRPC.

Molecular docking results

To further validate potential targets in CRPC, the molecular docking study was performed on the main components (kaempferol and triptolide) with the core target proteins (TP53, AKT1, PTGS2, TNF, VEGFA, and STAT3). The Binding Energy (BE) were predicted by docking analysis successfully, they were all negative and less than





-5, between the main components and target proteins. The lowest binding energy between molecules and gene proteins was shown in Table 1, and the smaller the binding energy between molecules, the better their docking properties were indicated. The results showed that kaempferol and PTGS2 had the best binding properties (Figure 9).

Discussion

Prostate cancer is one of the most common malignancies of the male urological system [5]. Perhaps 30% of initially diagnosed prostate cancer patients are metastatic Hormone-Sensitive Prostate Cancer (mHSPC), and most patients with early prostate cancer cases can still develop Castration-Resistant Prostate Cancer (CRPC) after Androgen Deprivation Therapy (ADT). Currently, there are androgen therapy, chemotherapy, radionuclide therapy, PARP inhibitors, and immunotherapy for the treatment of CRPC patients, but the efficacy and safety of these therapeutic measures remain unclear and have little impact on delaying disease progression in patients with CRPC. Therefore, we should innovate and explore new therapeutic approaches or combination therapy strategies to improve the prognosis of patients. We also should control the toxic effects of drugs and reduce adverse drug reactions as much as possible to improve the quality of life and prolong the survival time of patients.

Network pharmacology is an emerging discipline that combines bioinformatics, pharmacology, computer science, and other multidisciplinary theories to explore the network relationship between "compound-gene-disease" [16]. In our study, we explored the mechanism of action of TW for the treatment of CRPC, screened and identified the therapeutic targets using network pharmacology, then analyzed the mechanism of action and related signaling pathways using GO and KEGG enrichment analysis, and finally validated the binding energy between main components and key target proteins using molecular docking. Ultimately, we screened out the top 10 key targets, which include TP53, AKT1, TNF, VEGFA, STAT3, PTGS2, CXCL8, CASP3, MMP9, and ESR1.



Figure 7: GO and KEGG enrichment analyses. (a) The top 20 items of GO functional enrichment analyses of 38 overlapping targets. (b) The top 20 items of KEGG enrichment analyses of 38 overlapping targets.



Tumor Protein p53 (TP53) is a key Tumor Suppressor Gene (TSG). Mutations in this gene are associated with a variety of human cancers. TP53 plays a pivotal role in genomic stability, cell cycle arrest, DNA repair, apoptosis, and other important cellular functions and signaling pathways [17]. TP53 mutation, reported in 6.9% of PCa, is one of the most common alternations, affecting 50% of metastatic PCa cases [18]. Many studies have demonstrated that TP53 status has prognostic clinical significance in Castration-Resistant Prostate Cancer (CRPC), and its low expressions may predict a shorter survival time for CRPC [19]. Tumor Necrosis Factor (TNF), as a mediator of the inflammatory process, few studies have examined associations between TNF polymorphisms and prostate cancer risk [20]. But TNF may interact with other inflammatory genes to play a role in prostate cancer development, such as VEGFA, AKT, MiR-130b, etc. [21]. AKT1, which is a proto-oncogene, is frequently activated in the tumor, due to mutation or activation of the P13K, or inactivation of PTEN [22]. The activation of AKT1 can regulate multiple cellular functions, including the proliferation, survival, metabolism, motility, and angiogenesis of malignant cells [23]. Overexpression of AKT1 has been associated with the development of various tumors, including prostate cancer, gastric cancer, and ovarian cancer. Genetic variants and dysregulation of gene expression of PI3K pathway components were detected in prostate cancer and 100% of metastatic prostate cancer patients. It was also reported that AKT levels may be a predictor of biochemical recurrence in patients undergoing radical prostatectomy [24,25]. Vascular Endothelial Growth Factor A (VEGFA) is a member of the

PDGF/VEGF growth factor family, which can induce the proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. VEGFA is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Related research demonstrated that it is a strong negative association between VEGF and Prostate Specific Antigen (PSA) levels in PC patients [26]. Evidence also demonstrated the critical role of VEGF in tumor angiogenesis, and also suggested that VEGF has many properties of potential therapeutic targets whose inhibition would have specific anticancer effects [27]. The protein encoded by the Signal Transducer and Activator of Transcription 3 (STAT3) is activated through phosphorylation in response to various cytokines and growth factors including IL5, IL6, BMP2, and other gene proteins. In cancer cells, aberrant IL6 expression and intrinsic activation of STAT3 are closely associated with enhanced cancer cell proliferation. Overactivation of STAT3 plays a key role in malignant tumorigenesis, tumor progression, and metastatic dissemination. There were relevant reports indicating that IL-6 and STAT3 have a clear role in the progression of a substantial number of PCa patients [28]. STAT3 and STAT5A may be potential therapeutic targets in CRPC [29]. Prostaglandin-endoperoxide Synthase 2 (PTGS2), which has been shown to be expressed in most solid tumor types, such as colorectal cancer [30], pulmonary tumor [31], and prostate cancer [32], has been suggested as a target for chemoprevention, owing to its role in the development and progression of prostate cancer [33]. Furthermore, by inflammatory signaling through PTGS2 expression and ErbB family receptors/AKT activation, the progression from



Figure 9: Combined model diagram of core targets molecular docking. (a) VEGFA-triptolide; (b) AKT1- kaempferol; (c) PTGS2- kaempferol; (d) TNF- triptolide; (e) TP53- triptolide; (f) STAT3- triptolide.

androgen-sensitive PCa to CRPC is promoted [34]. C-X-C motif chemokine Ligand 8 (CXCL8), its encoded protein is commonly referred to as Interleukin-8 (IL-8). The increasing of IL8 secretion by PCa cells is associated with malignant biological behaviors of PCa cells. Poor clinicopathological features including high Gleason score and advanced pathological stage of PCa are associated with an increased mRNA expression of IL8 [35]. A combination of serum IL8 levels and f/tPSA ratios may provide a substantial improvement in predicting PCa patients' outcomes [36]. Moreover, elevated IL-8 in men with metastatic prostate cancer starting Androgen-Deprivation Therapy (ADT) is associated with a shorter time to castration resistance and overall survival [37]. Caspase 3 (CASP3) is a major mediator of apoptosis activated during radiotherapy or immunotherapy. It is often used as a marker for the effectiveness of cancer treatments. However, recent studies have suggested that CASP3 may promote tumor growth in a variety of ways, such as through the paracrine signaling pathway and providing a proangiogenic microenvironment [38,39]. Another recent study suggested that CASP3 may affect the survival time in patients after ADT for prostate cancer, so the analysis of CASP3 may help identify patients at higher risk of adverse prognosis in PCa patients [40]. Matrix Metallopeptidase 9 (MMP9), a recent study indicated that the expression level in cancerous tissues was significantly higher than the adjacent normal tissues in PCa. Furthermore, higher levels of MMP9 expression are strongly related to the Gleason score and age of PCa patients [41]. In addition, it has been reported that MMP9 protein is closely associated with mCRPC and the downregulation of MMP9 protein levels also can reduce the invasion and metastasis of CRPC cells [42]. It also has been demonstrated that the AKT signaling pathway also can affect the expression of MMP9 protein, leading to CRPC progression [43]. Estrogen Receptor 1 (ESR 1) is implicated in prostate cancer susceptibility by stimulating aberrant prostate growth, controlling prostate cell growth, and programming prostate cell death [44]. Recently, several ESR1 gene polymorphisms have been identified as candidates for prostate cancer susceptibility and among these, ESR1 PvuII (rs2234693 C>T) and XbaI (rs9340799 A>G) polymorphisms were suggested to possess significant associations with the development of prostate cancer. Both PvuII and XbaI can affect ESR1 transcription activity and possibly contribute to the elevated risk of prostate cancer [45]. but the exact effects of ESR1 gene mutations on prostate epithelial cells are still debated despite the fact that estrogen is already used in treating prostate cancer due to its growth-inhibitory effects.

In order to further explore the biological functions of TW for CRPC treatment, we performed GO enrichment analysis and KEGG pathway enrichment analysis on 38 intersectional targets, which showed that these targets are involved in multiple biological pathways to inhibit the proliferation and metastasis of prostate cancer cells, inhibit prostate cancer angiogenesis and promote apoptosis of prostate cancer cells. GO enrichment analysis showed that the biological processes of the overlapping targets were mainly enriched in the pathways of cell migration, apoptosis, oxidative stress response, the proliferation of immune cells, regulation of cell cycle, and autophagy regulation. The results of the KEGG pathway enrichment analysis showed that the treatment of CRPC with TW was mainly associated with AGE-RAGE signaling pathway in diabetic complications, chemotactic-receptor activation, proteoglycans in cancer, microRNA in cancer, endocrine resistance, p53 signaling pathway, estrogen signaling pathway, PI3K-Akt signaling pathway, IL-17 signaling

pathway, JAK-STAT signaling pathway, HIF-1 signaling pathway, and TNF signaling pathway. The PI3K/AKT pathway is the most commonly aberrantly activated signaling pathway in tumor cells, and aberrant activation of the PI3K-Akt pathway is associated with prostate cancer denervation resistance, disease progression, and poor prognosis [18,46]. It has been reported that activation of the PI3K/ AKT signaling pathway by AGE binding to RAGE may promote prostate cancer cell proliferation by regulating retinoblastoma protein. In addition, it has also been shown that PI3K/AKT pathway can contribute to prostate cancer development and progression through interacting with other cell signaling pathways, such as AR and the RAS/RAF/MEK signaling pathways. As reported by the study, the amplification of AR signaling, mutations in the ligandbinding domain of AR, and induction of AR splice variants have been shown to promote the development of CRPC [47]. Therefore, the development of PI3K/AKT pathway inhibitors in CRPC is extremely important.

In summary, this study initially investigated the key chemical components, action targets, and signaling pathways of TW for the treatment of CRPC, so as to exploit the effective therapeutic effects of TW. The related key targets can also be used as potential molecular markers for the diagnosis and treatment of CRPC. The molecular docking technique also verified the good binding between the key components and the key targets. This study laid a certain theoretical foundation for the treatment of CRPC by TW and also provided some ideas for the subsequent experimental design and research.

Conclusion

This present study revealed the potential mechanisms of *Tripterygium wilfordii* in treating castration-resistant prostate cancer through multiple targets and signaling pathways, the molecular docking technology also validated the high affinity between the main bioactive components in *Tripterygium wilfordii* and the core targets in CRPC. Furthermore, the present study provided a reference for the wide application of TW in clinically managing CRPC.

Acknowledgment

The authors are highly grateful to the First Affiliated Hospital of Sun Yat-sen University, and the grants for supporting this research work.

Funding

This study was supported by grants from the National Natural Science Foundation of China (No. 81502219).

References

- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49.
- Wei Y, Wu J, Gu W, Qin X, Dai B, Lin G, et al. Germline DNA repair gene mutation landscape in Chinese prostate cancer patients. Eur Urol. 2019;76(3):280-3.
- Chen WQ, Zheng RS, Zhang SW, Zeng HM, Zou XN, He J. Analysis of cancer incidence and mortality in elderly population in China, 2013. Zhonghua Zhong Liu Za Zhi. 2017;39(1):60-6.
- Lin HN, Gu XY, Zhang SW, Zeng HM, Wei WW, Zheng RS. Analysis on incidence and mean age at diagnosis for Global Cancer. Zhonghua Zhong Liu Za Zhi. 2018;40(7):543-9.

- Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-32.
- 6. Albertsen PC. Prostate cancer screening and treatment: where have we come from and where are we going? BJU Int. 2020;126(2):218-24.
- 7. Taneja SS. Re: Darolutamide in nonmetastatic, castration-resistant prostate cancer. J Urol. 2019;202(4):660-1.
- 8. Taneja SS. Re: Enzalutamide in men with nonmetastatic, castrationresistant prostate cancer editorial comment. J Urol. 2019;201(1):31.
- 9. Saad F, Efstathiou E, Attard G, Flaig TW, Franke F, Goodman Jr OB, et al. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): A randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2021;22():1541-59.
- Tsaur I, Brandt MP, Juengel E, Manceau C, Ploussard G. Immunotherapy in prostate cancer: New horizon of hurdles and hopes. World J Urol. 2021;39(5):1387-403.
- 11. Wang X, Zheng M, Fei F, Li C, Du J, Liu K, et al. EMT-related protein expression in polyploid giant cancer cells and their daughter cells with different passages after triptolide treatment. Med Oncol. 2019;36(9):82.
- 12. Deng QD, Lei XP, Zhong YH, Chen MS, Ke YY, Li Z, et al. Triptolide suppresses the growth and metastasis of non-small cell lung cancer by inhibiting β-catenin-mediated epithelial-mesenchymal transition. Acta Pharmacol Sin. 2021;42(9):1486-97.
- Qin G, Li P, Xue Z. Triptolide induces protective autophagy and apoptosis in human cervical cancer cells by downregulating Akt/mTOR activation. Oncol Lett. 2018;16(3):3929-34.
- 14. Hayashi M, Madokoro H, Yamada K, Nishida H, Morimoto C, Sakamoto M, et al. Novel antibody-drug conjugate with anti-CD26 humanized monoclonal antibody and Transcription Factor IIH (TFIIH) inhibitor, triptolide, inhibits tumor growth *via* impairing mRNA synthesis. Cancers (Basel). 2019;11(8):1138.
- Zhao S, Iyengar R. Systems pharmacology: Network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol. 2012;52:505-21.
- 16. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682-90.
- 17. Muller PAJ, Vousden KH. Mutant p53 in cancer: New functions and therapeutic opportunities. Cancer Cell. 2014;25(3):304-17.
- Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215-28.
- 19. Soerohardjo I, Widodo I, Heriyanto DS, Zulfiqqar A, Anwar SL. Downregulation of RB1 and TP53 as potential predicting biomarkers for Castration-Resistant Prostate Cancer (CRPC): Indonesian retrospective cohort study. Ann Med Surg (Lond). 2020;60:549-54.
- 20. Pardo T, Salcedo P, Quintero JM, Borjas L, Fernández-Mestre M, Sánchez Y, et al. [Study of the association between the polymorphism of the TNF- α gene and prostate cáncer]. Rev Alerg Mex. 2019;66(2):154-62.
- 21. Mu HQ, He YH, Wang SB, Yang S, Wang YJ, Nan CJ, et al. MiR-130b/ TNF- α /NF- κ B/VEGFA loop inhibits prostate cancer angiogenesis. Clin Transl Oncol. 2020;22(1):111-21.
- 22. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell. 2000;100(4):387-90.
- 23. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489-501.
- 24. Hammarsten P, Cipriano M, Josefsson A, Stattin P, Egevad L, Granfors T, et al. Phospho-Akt immunoreactivity in prostate cancer: Relationship to disease severity and outcome, Ki67 and phosphorylated EGFR expression.

PLoS One. 2012;7(10):e47994.

- Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11-22.
- 26. Trapeznikova MF, Shibayev AN, Kazantseva IA, Mironova OS, Gurevich LE, Morozov AP, et al. Vascular endothelial growth factor in patients with prostate cancer and benign prostatic hyperplasia. Vestn Ross Akad Med Nauk. 2005;(5):14-6.
- 27. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69 Suppl 3:4-10.
- 28. Culig Z. STAT3 in Prostate Cancer: Whom should we treat and when? Eur Urol. 2017;71(3):317-8.
- 29. Mohanty SK, Yagiz K, Pradhan D, Luthringer DJ, Amin MB, Alkan S, et al. STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer. Oncotarget. 2017;8:85997-6010.
- 30. Kunzmann AT, Murray LJ, Cardwell CR, McShane CM, McMenamin UC, Cantwell MM. PTGS2 (Cyclooxygenase-2) expression and survival among colorectal cancer patients: A systematic review. Cancer Epidemiol Biomarkers Prev. 2013;22(9):1490-7.
- Castelao JE, Bart RD, 3rd, DiPerna CA, Sievers EM, Bremner RM. Lung cancer and cyclooxygenase-2. Ann Thorac Surg. 2003;76(4):1327-35.
- 32. Danforth KN, Hayes RB, Rodriguez C, Yu K, Sakoda LC, Huang WY, et al. Polymorphic variants in PTGS2 and prostate cancer risk: Results from two large nested case-control studies. Carcinogenesis. 2008;29(3):568-72.
- 33. Fenner A. Prostate cancer: A COX-2 far? Nat Rev Urol. 2016;13:496.
- 34. Benelli R, Barboro P, Costa D, Astigiano S, Barbieri O, Capaia M, et al. Multifocal signal modulation therapy by celecoxib: A strategy for managing castration-resistant prostate cancer. Int J Mol Sci. 2019;20(23):6091.
- 35. Uehara H, Troncoso P, Johnston D, Bucana CD, Dinney C, Dong Z, et al. Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate. 2005;64(1):40-9.
- 36. Veltri RW, Miller MC, Zhao G, Ng A, Marley GM, Wright Jr GL, et al. Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology. 1999;53(1):139-47.
- 37. Sharma J, Gray KP, Harshman LC, Evan C, Nakabayashi M, Fichorova R, et al. Elevated IL-8, TNF- α , and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate. 2014;74(8):820-8.
- 38. Feng X, Yu Y, He S, Cheng J, Gong Y, Zhang Z, et al. Dying glioma cells establish a proangiogenic microenvironment through a caspase 3 dependent mechanism. Cancer Lett. 2017;385:12-20.
- 39. Huang Q, Li F, Liu X, Li W, Shi W, Liu FF, et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med. 2011;17(7):860-6.
- 40. Huang SP, Bao BY, Hour TC, Huang CY, Yu CC, Liu CC, et al. Genetic variants in CASP3, BMP5, and IRS2 genes may influence survival in prostate cancer patients receiving androgen-deprivation therapy. PLoS One. 2012;7(7):e41219.
- 41. Pouyanfar N, Monabbati A, Sharifi AA, Dianatpour M. Expression levels of MMP9 and PIWIL2 in prostate cancer: A case-control study. Clin Lab. 2016;62(4):651-7.
- Sun Q, Hu LL, Fu Q. MCT4 promotes cell proliferation and invasion of castration-resistant prostate cancer PC-3 cell line. EXCLI J. 2019;18:187-94.
- 43. Sáez-Martínez P, Jiménez-Vacas JM, León-González AJ, Herrero-Aguayo V, Hidalgo AJM, Gómez-Gómez E, et al. Unleashing the diagnostic, prognostic and therapeutic potential of the neuronostatin/GPR107 system

in prostate cancer. J Clin Med. 2020;9(6):1703.

- 44. Langley RE, Godsland IF, Kynaston H, Clarke NW, Rosen SD, Morgan RC, et al. Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer. BJU Int. 2008;102(4):442-5.
- 45. Wang YM, Liu ZW, Guo JB, Wang XF, Zhao XX, Zheng X. ESR1 gene polymorphisms and prostate cancer risk: A HuGE review and metaanalysis. PLoS One. 2013;8(6):e66999.
- 46. Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019;116(23):11428-36.
- Bitting RL, Armstrong AJ. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer. 2013;20(3):R83-99.